Omitting 5-FU Bolus Does Not Reduce Survival in Advanced Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 10, 2024 -- Omission of 5-fluorouracil (5-FU) from the first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens is not associated with reduced survival among patients with advanced colorectal, gastroesophageal, and pancreatic cancers, according to a study published online Sept. 5 in the Journal of the National Comprehensive Cancer Network.
Chengwei Peng, M.D., from New York University in New York City, and colleagues queried a real-world database for patients with advanced colorectal, gastroesophageal, and pancreatic cancers (8,670, 1,481, and 1,614 patients, respectively) who received first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens to examine whether omission of the 5-FU bolus is associated with a difference in survival and toxicity.
Overall, 86.3 and 13.7 percent of patients received and did not receive a 5-FU bolus, respectively. The researchers found that omitting the bolus was not associated with a reduction in overall survival after inverse probability of treatment-weighted analysis. However, there were significant associations for bolus omission with reductions in neutropenia (10.7 versus 22.7 percent), thrombocytopenia (11.2 versus 16.1 percent), and use of granulocyte colony-stimulating factor (19.6 versus 29.1 percent) after treatment.
"Our data suggest that omitting the 5-FU bolus may lead to reduced treatment toxicity without compromising efficacy. Future prospective studies are needed to confirm these findings, especially applicability to the adjuvant setting," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Cannabis Use Disorder Linked to Increased Risk for Oral Cancer
FRIDAY, Aug. 1, 2025 -- Cannabis use disorder (CUD) is associated with an increased risk for oral cancer, according to a study published in the September issue of Preventive...
Racialized Economic Segregation Linked to Advanced Cancer Diagnosis
FRIDAY, Aug. 1, 2025 -- People living in racially and economically segregated neighborhoods are more likely to be diagnosed with advanced-stage breast and cervical cancer...
COVID-19 Vaccine Boosters Aid Outcomes in Patients With Cancer
TUESDAY, July 29, 2025 -- COVID-19 vaccination boosters protect people with cancer developing from severe COVID-19, according to a study published online July 17 in JAMA...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.